Arca
Skip to content
Tools
Tools

Label Changes: Zepzelca (lurbinectedin)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Zepzelca label DailyMed has published, from Jazz Pharmaceuticals, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 10
  • Sections changed, version 9 to 10: 7

What changed from version 9 to version 10

Mar 16, 2026 to Oct 2, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 72 removed
  2. Dosage and administrationChanged · 61 words added, 112 removed
  3. Warnings and precautionsChanged · 7 words added, 231 removed
  4. Adverse reactionsChanged · 24 words added, 766 removed
  5. Use in specific populationsChanged · 144 removed
  6. Clinical studiesChanged · 6 words added, 544 removed
  7. Patient informationChanged · 23 words added, 94 removed

Indications and usage

Changed72 removed
2 unchanged lines
ZEPZELCA, in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide.
1.2 Metastatic Small Cell Lung Cancer
ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Dosage and administration

Changed61 words added, 112 removed
1 unchanged line
2.1 Recommended Dosage
The recommended dosage of ZEPZELCA as a single-agent and as ain combination with atezolizumab or atezolizumab and hyaluronidase-tqjs is 3.2 mg/m2 by intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity [see Dosage and Administration (2.4)].
Initiate treatment with ZEPZELCA only if absolute neutrophil count (ANC) is at least 1,500 cells/mm3 and platelet count is at least 100,000/mm3 [see Warnings and Precautions (5.1)].
ZEPZELCA with Intravenous Atezolizumab or atezolizumab and hyaluronidase-tqjs
When administering ZEPZELCA on the same day as atezolizumab or atezolizumab and hyaluronidase-tqjs, administer the chosen atezolizumab drug first. For the recommended dosage of atezolizumab or atezolizumab and hyaluronidase-tqjs refer to the respective Prescribing Information.
If discontinuation of atezolizumab or atezolizumab and hyaluronidase-tqjs is required due to an immune-related severe adverse event, treatment with ZEPZELCA may be continued at the same dose as a single agent. If immune toxicity does not resolve or recurs despite discontinuation of atezolizumab, permanently discontinue ZEPZELCA.
2.2 Dosage Modifications for Adverse Reactions
The recommended dose reductions for adverse reactions are listed in Table 1.
Permanently discontinue ZEPZELCA in patients who require a dose interruption of greater than two weeks and in patients who are unable to tolerate 2 mg/m2the everysecond 21dose daysreduction.
Table 1: Dose Reduction for ZEPZELCA for Adverse Reactions
6 unchanged lines
Adverse Reaction | Severitya | Dosage Modification
Neutropeniab [see Warnings and Precautions (5.1)] | Grade 4 or Any grade febrile neutropenia | •Withhold ZEPZELCA until absolute neutrophil count (ANC) is ≥ 15001,500 cells/mm3 •Resume ZEPZELCA at a reduced dose
Thrombocytopenia [see Warnings and Precautions (5.1)] | Grade 3 with bleeding or Grade 4 | •Withhold ZEPZELCA until platelet ≥ 100,000/mm3 •Resume ZEPZELCA at reduced dose
3 unchanged lines
Grade ≥ 3 | •Permanently discontinue ZEPZELCA
Other Adverse Reactions [see Adverse Reactions (6.1), and Postmarketing Experience (6.2)] | Grade 2 | •Withhold ZEPZELCA until Grade ≤ 1 •Resume ZEPZELCA at same dose
Grade ≥ 3 | •Withhold ZEPZELCA until Grade ≤ 1 •Resume ZEPZELCA at reduced dose or permanently discontinue
2.3 Dosage Modifications for Use with Strong andor Moderate CYP3A Inhibitors
Avoid coadministration of ZEPZELCA with strong or moderate CYP3A inhibitors. If coadministration of ZEPZELCA with a strong or moderate CYP3A inhibitor cannot be avoided, reduce the dose of ZEPZELCA by 50% [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. After discontinuation of a strong or moderate CYP3A inhibitor for 5 half-lives of the inhibitor, increase the ZEPZELCA dose to the dose used before starting the inhibitor.
2.4 Dosage Modifications for Patients with Severe andor Moderate Hepatic Impairment
Avoid administration of ZEPZELCA in patients with severe hepatic impairment (total bilirubin > 3 × Upper Limit of Normal (ULN)). If administration of ZEPZELCA cannot be avoided, the recommended dosage is 1.6 mg/m2 by intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity [see Use In Specific Populations (8.6) and Clinical Pharmacology (12.3)].
In patients with moderate hepatic impairment (total bilirubin > 1.5 to ≤ 3 × ULN and any AST), the recommended dosage of ZEPZELCA is 1.6 mg/m2 by intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity.
For patients with baseline severe or moderate hepatic impairment who experience intolerable adverse reactions at the 1.6 mg/m2 recommended dosage, permanently discontinue ZEPZELCA.
2.5 Recommended Prophylactic Medications
ZEPZELCA as a Single Agent
Consider administering the following pre-infusion medications for antiemetic prophylaxis [see Adverse Reactions (6.1)]:
•Corticosteroids (dexamethasone 8 mg intravenously or equivalent)
•Serotonin antagonists (ondansetron 8 mg intravenously or equivalent)
ZEPZELCA with Intravenous Atezolizumab or atezolizumab and hyaluronidase-tqjs
• To reduce the risk of febrile neutropenia during treatment with ZEPZELCA in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, administer granulocyte colony-stimulating factor (G-CSF) [Refer to Prescribing Information].
• To reduce the risk of febrile neutropenia, administer granulocyte colony-stimulating factor (G-CSF) [Refer to Prescribing Information].
• To reduce the risk of nausea, administer the following pre-infusion medications for antiemetic prophylaxis prior to Cycle 1 and consider administering for subsequent cycles [see Adverse Reactions (6.1)] :
⸰ Corticosteroids (dexamethasone 8 mg or equivalent intravenously)
12 unchanged lines
•ZEPZELCA can be administered with or without an in-line filter. If infusion lines containing in-line filters are utilized for administration of ZEPZELCA, polyethersulfone (PES) in-line filters with pore sizes of 0.22 micron are recommended. oDo not use in-line nylon membrane filters when the reconstituted ZEPZELCA solution is diluted using 0.9% Sodium Chloride Injection, USP. Adsorption of ZEPZELCA to the Nylon membrane filters has been observed when 0.9% Sodium Chloride Injection, USP is used as the diluent.
•Compatibility with other intravenous administration materials and the diluted ZEPZELCA solution has been demonstrated in the following materials: oContainers: Polyolefin containers (polyethylene, polypropylene and mixtures). oInfusion sets: Polyvinyl Chloride (PVC) (non-DEHP-containing), polyurethane and polyolefin infusion sets (polyethylene, polypropylene, and polybutadiene). oImplantable venous access systems: Implantable venous access systems with titanium and plastic resin ports and with polyurethane or silicone intravenous catheters.
•Do not co-administer ZEPZELCA and other intravenous drugs concurrently within the same intravenous line.
ZEPZELCA with Intravenous Atezolizumab or atezolizumab and hyaluronidase -tqjs
• Administer either atezolizumab or atezolizumab and hyaluronidase-tqjs first, then administer ZEPZELCA. For the recommended dosage of atezolizumab or atezolizumab and hyaluronidase-tqjs refer to the respective Prescribing Information.
2 unchanged lines

Warnings and precautions

Changed7 words added, 231 removed
2 unchanged lines
ZEPZELCA can cause severe and fatal myelosuppression including febrile neutropenia and sepsis, thrombocytopenia and anemia.
Administer ZEPZELCA only to patients with baseline neutrophil count of at least 1,500 cells/mm3 and platelet count of at least 100,000/mm3. To reduce the risk of febrile neutropenia during treatment with ZEPZELCA in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, administer granulocyte colony-stimulating factor (G-CSF) [refer to Prescribing Information].
Monitor blood counts including neutrophils, red blood cells and platelets prior to each ZEPZELCA administration. For neutrophil count less than 500 cells/mm3 or any value less than lower limit of normal, administer G-CSF. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity [see Dosage and Administration (2.2)].
ZEPZELCA with Intravenous Atezolizumab
In the IMforte study [see Adverse Reactions (6.1)], primary prophylaxis of G-CSF was administered to 84% of patients. Based on laboratory values, decreased neutrophils occurred in 36%, including 18% Grade 3 or Grade 4 in patients who received ZEPZELCA in combination with atezolizumab. The median time to onset of Grade 3 and 4 decreased neutrophil cells was 31 days and a median duration of 10 days. Febrile neutropenia occurred in 1.7%. Sepsis occurred in 1%. There were 7 fatal infections: pneumonia (n=3), sepsis (n=3), and febrile neutropenia (n=1).
1 unchanged line
Based on laboratory values, decreased hemoglobin occurred in 51%, including 13% Grade 3 or Grade 4 in patients who received ZEPZELCA in combination with atezolizumab. The median time to onset of Grade 3 and 4 decreased hemoglobin was 64 days and a median duration of 8 days.
ZEPZELCA as a Single Agent
In clinical studies of 554 patients with advanced solid tumors receiving ZEPZELCA as a single agent [see Adverse Reactions (6.1) ], Grade 3 or 4 neutropenia occurred in 41% of patients, with a median time to onset of 15 days and a median duration of 7 days. Febrile neutropenia occurred in 7% of patients. Sepsis occurred in 2% of patients and was fatal in 1% (all cases occurred in patients with solid tumors other than SCLC). Grade 3 or 4 thrombocytopenia occurred in 10%, with a median time to onset of 10 days and a median duration of 7 days. Grade 3 or 4 anemia occurred in 17% of patients.
5.2 Hepatotoxicity
1 unchanged line
Monitor liver function tests prior to initiating ZEPZELCA and periodically during treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity [see Dosage and Administration (2.2)].
ZEPZELCA with Intravenous Atezolizumab
In the IMforte study [see Adverse Reactions (6.1)], based on laboratory values, increased alanine aminotransferase (ALT) occurred in 25%, including 3% Grade 3 or Grade 4 in patients who received ZEPZELCA in combination with atezolizumab. Increased aspartate aminotransferase (AST) occurred in 24% including 3% Grade 3 or Grade 4. The median time to onset of Grade ≥ 3 elevation in transaminases was 52 days (range: 6 to 337).
ZEPZELCA as a Single Agent
In clinical studies of 554 patients with advanced solid tumors receiving ZEPZELCA as a single agent [see Adverse Reactions (6.1) ], Grade 3 elevations of ALT and AST were observed in 6% and 3% of patients, respectively, and Grade 4 elevations of ALT and AST were observed in 0.4% and 0.5% of patients, respectively. The median time to onset of Grade ≥ 3 elevation in transaminases was 8 days (range: 3 to 49), with a median duration of 7 days.
5.3 Extravasation Resulting in Tissue Necrosis
Extravasation of ZEPZELCA can cause skin and soft tissue injury, including necrosis requiring debridement. Consider use of a central venous catheter to reduce the risk of extravasation, particularly in patients with limited venous access. Monitor patients for signs and symptoms of extravasation during the ZEPZELCA infusion. If extravasation occurs, immediately discontinue the infusion, remove the infusion catheter, and monitor for signs and symptoms of tissue necrosis. The time to onset of necrosis after extravasation may vary.
ZEPZELCA with Intravenous Atezolizumab
In the IMforte study [see Adverse Reactions (6.1)], extravasation resulting in skin necrosis occurred in one patient who received ZEPZELCA in combination with atezolizumab.
3 unchanged lines
Monitor creatine phosphokinase (CPK) prior to initiating ZEPZELCA and periodically during treatment as clinically indicated. Withhold or reduce the dose based on severity [see Dosage and Administration (2.2)].
ZEPZELCA with Intravenous Atezolizumab
In the IMforte study [see Adverse Reactions (6.1)], among 235 patients who had a creatine phosphokinase laboratory evaluation, increased creatine phosphokinase occurred in 9% who received ZEPZELCA in combination with atezolizumab.
5.5 Embryo-Fetal Toxicity
Based on animal data and its mechanism of action [see Clinical Pharmacology (12.1) ] ZEPZELCA can cause fetal harm when administered to a pregnant woman. Intravenous administration of a single dose of lurbinectedin (approximately 0.2 times the 3.2 mg/m2 clinical dose) to pregnant animals during the period of organogenesis caused 100% embryolethalityembryo lethality in rats. Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 7 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 4 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

Adverse reactions

Changed24 words added, 766 removed
7 unchanged lines
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to ZEPZELCA in combination with intravenous atezolizumab in the IMforte study [see Clinical Studies (14.1)], in 242 patients with extensive stage small cell lung cancer (ES-SCLC) whose disease had not progressed after initial therapy with atezolizumab, carboplatin, and etoposide. Patients received ZEPZELCA 3.2 mg/m2 intravenously (IV) in combination with atezolizumab 12001,200 mg IV every 21 days until disease progression or unacceptable toxicity. Among 242 patients who received ZEPZELCA in combination with intravenous atezolizumab, 34% were exposed for 6 months or longer and 8% were exposed for greater than one year. The most common adverse reactions (≥ 3015%), including laboratory abnormalities, in patients who received ZEPZELCA with atezolizumab were decreased lymphocytes, decreased platelets, decreased hemoglobin, decreased neutrophils, nausea, fatigue, increased alkaline phosphatase, decreased sodium, increased ALT, increased AST, decreased calcium, increased creatinine, musculoskeletal pain, decreased appetite and fatigue/astheniadiarrhea.
The pooled safety population described in the WARNINGS AND PRECAUTIONS also reflects exposure to ZEPZELCA as a single agent at a dose of 3.2 mg/m2 intravenously every 21 days in 554 patients with advanced solid tumors. Among 554 patients who received ZEPZELCA, including 105 patients with small cell lung cancer (SCLC) in PM1183-B-005-14 (Study B-005), 24% were exposed for 6 months or longer and 5% were exposed for greater than one year. The most common adverse reactions for ZEPZELCA as a single agent, (Study B-005), including laboratory abnormalities, (≥ 20%) are leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhea.
Extensive-Stage Small Cell Lung Cancer (IMforte)
The safety of ZEPZELCA in combination with intravenous (IV) atezolizumab was evaluated in IMforte [see Clinical Studies (14)]. Patients received intravenous ZEPZELCA 3.2 mg/m2 in combination with intravenous atezolizumab 12001,200 mg on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Primary prophylaxis of G-CSF was administered to 84% of patients. Among 242 patients who received ZEPZELCA with atezolizumab, the median duration of exposure to lurbinectedin was 4.1 months, 33% were exposed for 6 months or longer and 8% were exposed for greater than one year.
The median age of patients who received ZEPZELCA in combination with intravenous atezolizumab was 66 years (range: 35 to 85); 62% male; 82% White, 13% Asian, and 0.8% Black or African American.
2 unchanged lines
Dosage interruptions of ZEPZELCA due to an adverse reaction occurred in 25%. Adverse reactions which required dosage interruption in ≥ 2% of patients included anemia, fatigue, decreased neutrophil count, and decreased platelet count.
Dose reductions of ZEPZELCA due to an adverse reaction occurred in 15% of patients. Adverse reactions which required dosage reduction in ≥ 2% of patients included decreased platelet count, fatigue, nausea, and vomiting.
Table 3 summarizes the adverse reactions in IMforte.
40 unchanged lines
Increased creatinine | 21 | 3 | 14 | 0
Metastatic Small Cell Lung Cancer (SCLC) (Study B-005)
The safety of ZEPZELCA was evaluated in a cohort of 105 patients with previously treated SCLC in Study B-005 [see Clinical Studies (14)]. Patients received ZEPZELCA 3.2 mg/m2 intravenously every 21 days. All patients in this study received a pre-specified anti-emetic regimen consisting of a corticosteroid and serotonin antagonist. Patients could receive G-CSF for secondary prophylaxis (i.e., after patients had an initial decrease in WBC), but not primary prophylaxis. Among patients who received ZEPZELCA, 29% were exposed for 6 months or longer and 6% were exposed for greater than one year.
Serious adverse reactions occurred in 34% of patients who received ZEPZELCA. Serious adverse reactions in ≥ 3% of patients included pneumonia, febrile neutropenia, neutropenia, respiratory tract infection, anemia, dyspnea, and thrombocytopenia.
Permanent discontinuation due to an adverse reaction occurred in two patients (1.9%) who received ZEPZELCA. Adverse reactions resulting in permanent discontinuation in ≥ 1% of patients who received ZEPZELCA, which included peripheral neuropathy and myelosuppression.
Dosage interruptions due to an adverse reaction occurred in 30.5% of patients who received ZEPZELCA. Adverse reactions requiring dosage interruption in ≥ 3% of patients who received ZEPZELCA included neutropenia, and hypoalbuminemia.
Dose reductions due to an adverse reaction occurred in 25% of patients who received ZEPZELCA. Adverse reactions requiring dosage reductions in ≥ 3% of patients who received ZEPZELCA included neutropenia, febrile neutropenia and fatigue.
The most common adverse reactions, including laboratory abnormalities, (≥ 20%) were leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhea.
Table 5 summarizes the adverse reactions in the SCLC cohort of Study B-005.
Table 5: Adverse Reactions (≥ 10%) in Patients with SCLC Who Received ZEPZELCA in Study B-005
a Graded per NCI CTCAE 4.0.
b No grade 5 adverse reactions were reported.
c Includes abdominal pain, abdominal pain upper and abdominal discomfort.
d Includes musculoskeletal pain, back pain, arthralgia, pain in extremity, musculoskeletal chest pain, neck pain, bone pain and myalgia.
e Includes cough and productive cough.
f Includes upper respiratory tract infection, viral upper respiratory tract infection, respiratory tract infection and bronchitis.
g Includes pneumonia and lung infection.
h Includes neuropathy peripheral, neuralgia, paresthesia, peripheral sensory neuropathy, hypoesthesia, and hyperesthesia.
Adverse Reaction | ZEPZELCA (n=105)
All Grades a,b (%) | Grades 3-4 (%)
General disorders | |
Fatigue | 77 | 12
Pyrexia | 13 | 0
Chest pain | 10 | 0
Gastrointestinal disorders | |
Nausea | 37 | 0
Constipation | 31 | 0
Vomiting | 22 | 0
Diarrhea | 20 | 4
Abdominal painc | 11 | 1
Musculoskeletal and connective tissue disorders | |
Musculoskeletal paind | 33 | 4
Metabolism and nutrition disorders | |
Decreased appetite | 33 | 1
Respiratory, thoracic and mediastinal disorders | |
Dyspnea | 31 | 6
Coughe | 20 | 0
Infections and infestations | |
Respiratory tract infectionf | 18 | 5
Pneumoniag | 10 | 7
Nervous system disorders | |
Peripheral neuropathyh | 11 | 1
Headache | 10 | 1
Clinically relevant adverse reactions in < 10% of patients who received ZEPZELCA include dysgeusia, febrile neutropenia and pneumonitis.
Table 6 summarizes the laboratory abnormalities in Study B-005.
Table 6: Select Laboratory Abnormalities (≥ 20%) Worsening from Baseline in Patients with SCLC Who Received ZEPZELCA in Study B-005
a The denominator used to calculate the rate varied from 95 to 105 based on the number of patients with a baseline value and at least one post-treatment value.
b Graded per NCI CTCAE 4.0.
Laboratory Abnormality | ZEPZELCAa (n=105)
All Gradesb (%) | Grades 3-4 (%)
Hematology | |
Decreased leukocytes | 79 | 29
Decreased lymphocytes | 79 | 43
Decreased hemoglobin | 74 | 10
Decreased neutrophils | 71 | 46
Decreased platelets | 37 | 7
Chemistry | |
Increased creatinine | 69 | 0
Increased alanine aminotransferase | 66 | 4
Increased glucose | 52 | 5
Decreased albumin | 32 | 1
Decreased sodium | 31 | 7
Increased aspartate aminotransferase | 26 | 2
Decreased magnesium | 22 | 0
6.2 Postmarketing Experience
4 unchanged lines

Use in specific populations

Changed144 removed
23 unchanged lines
8.5 Geriatric Use
ZEPZELCA with Intravenous Atezolizumab
Of the 242 patients with ES-SCLC treated with ZEPZELCA and atezolizumab in IMforte, 124 (51%) patients were 65 years of age and older, while 29 (12%) patients were 75 years of age and older. No overall differences in effectiveness were observed between older and younger patients. There was no overall difference in the incidence of serious adverse reactions in patients ≥ 65 years of age and patients < 65 years of age (33% vs. 29%, respectively). There was a higher incidence of Grade 3 or 4 adverse reactions in patients ≥ 65 years of age compared to younger patients (45% vs. 31%, respectively).
ZEPZELCA as a Single Agent
Of the 105 patients with SCLC administered ZEPZELCA in clinical studies, 37 (35%) patients were 65 years of age and older, while 9 (9%) patients were 75 years of age and older. No overall difference in effectiveness was observed between patients aged 65 and older and younger patients.
There was a higher incidence of serious adverse reactions in patients ≥ 65 years of age than in patients < 65 years of age (49% vs. 26%, respectively). The serious adverse reactions most frequently reported in patients ≥ 65 years of age were related to myelosuppression and consisted of febrile neutropenia (11%), neutropenia (11%), thrombocytopenia (8%), and anemia (8%) [see Adverse Reactions (6.1) ]. There was a higher incidence of Grade 3 or 4 adverse reactions in patients ≥ 65 years of age compared to younger patients (76% vs. 50%, respectively).
8.6 Hepatic Impairment
3 unchanged lines

Clinical studies

Changed6 words added, 544 removed
3 unchanged lines
The trial randomized 483 patients who had not experienced disease progression following the completion of 4 cycles of intravenous atezolizumab with carboplatin and etoposide 1:1 to one of the following treatment arms:
•ZEPZELCA 3.2 mg/m2 IV with atezolizumab 12001,200 mg IV once every 3 weeks until disease progression or unacceptable toxicity, or
•Atezolizumab 12001,200 mg IV once every 3 weeks until disease progression or unacceptable toxicity
Randomization was stratified by ECOG performance status prior to randomization (0 vs. 1), lactate dehydrogenase (LDH) (≤ ULN vs. > ULN) prior to randomization, presence of liver metastases prior to initial study enrollment (yes vs. no), and prior receipt of prophylactic cranial irradiation (yes vs. no).
1 unchanged line
A total of 483 patients were randomized, including 242 to the ZEPZELCA with atezolizumab arm and 241 to the atezolizumab arm. The median age was 66 years (range 35 to 85); 63% male; 82% White, 13% Asian, 0.8% were Black or African American; 7% were of Hispanic or Latino ethnicity; and 98% were current or previous smokers. Baseline ECOG performance status was 0 (43%) or 1 (57%).
Efficacy results are presented in Table 75 and Figures 1 and 2.
Table 75: Efficacy Results from IMforte
1Measured from the time of randomization
19 unchanged lines
p-value3, 7 | < 0.0001
14.2 Metastatic Small Cell Lung Cancer
PM1183-B-005-14 (Study B-005; NCT02454972) is a multicenter, open-label, multi-cohort trial evaluating ZEPZELCA as a single agent in patients with advanced or metastatic solid tumors. A cohort of patients with small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy received ZEPZELCA 3.2 mg/m2 by intravenous infusion every 21 days (one cycle). Patients received a median of 4 cycles of ZEPZELCA (range 1 to 24 cycles). The trial excluded patients with central nervous system (CNS) involvement, grade ≥ 3 dyspnea, daily intermittent oxygen requirement, hepatitis or cirrhosis, and immunocompromised patients. Tumor assessments were conducted every 6 weeks for the first 18 weeks and every 9 weeks thereafter. The major efficacy outcome measure was confirmed investigator-assessed overall response rate (ORR). Additional efficacy outcome measures included duration of response (DoR), and an Independent Review Committee (IRC) assessed ORR using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
A total of 105 patients with SCLC who progressed on or after platinum-based chemotherapy were enrolled. The median age was 60 years (range: 40 to 83) with 65% of patients < 65 years and 35% of patients ≥ 65 years, and 60% were male. The majority (75%) of the patients were White, 1% were Asian, 1% were Black and 23% were not reported. Baseline ECOG performance status was 0 or 1 in 92% of patients, and 92% were former/current smokers. All patients received at least one line of platinum-based chemotherapy (range 1-2 lines), and prior radiotherapy had been administered to 71% of patients. Eight patients (8%) had prior immunotherapy in addition to platinum-based chemotherapy. Sixty patients (57%) had platinum-sensitive SCLC, defined as recurrence or progression ≥ 90 days after the last dose of platinum-containing therapy (chemotherapy free interval [CTFI] ≥ 90 days). The remaining 45 patients had platinum-resistant SCLC, defined as recurrence or progression < 90 days after the last dose of platinum-containing therapy (CTFI < 90 days).
Table 8 summarizes investigator-assessed and independent review committee assessed key efficacy measures in all patients and in platinum-resistant and platinum-sensitive subgroups.
Table 8: Efficacy Results in SCLC Cohort of Study B-005
CI: confidence interval, CTFI: chemotherapy free interval.
a Confirmed overall response rate.
b Based on observed duration of response.
Investigator Assessed Responsea | ZEPZELCA All Patients (n=105) | ZEPZELCA CTFI < 90 days (n=45) | ZEPZELCA CTFI ≥ 90 days (n=60)
Overall Response Rate (95% CI) | 35% (26%, 45%) | 22% (11%, 37%) | 45% (32%, 58%)
Complete response | 0% | 0% | 0%
Partial response | 35% | 22% | 45%
Duration of Response | | |
Median in months (95% CI) | 5.3 (4.1, 6.4) | 4.7 (2.6, 5.6) | 6.2 (3.5, 7.3)
% with ≥ 6 monthsb | 35% | 10% | 44%
Independent Review Committee Assessed Responsea | All Patients (n=105) | CTFI < 90 days (n=45) | CTFI ≥ 90 days (n=60)
Overall Response Rate (95% CI) | 30% (22%, 40%) | 13% (5%, 27%) | 43% (31%, 57%)
Complete response | 0% | 0% | 0%
Partial response | 30% | 13% | 43%
Duration of Response | | |
Median in months (95% CI) | 5.1 (4.9, 6.4) | 4.8 (2.4, 5.3) | 5.3 (4.9, 7.0)
% with ≥ 6 monthsb | 25% | 0% | 31%

Patient information

Changed23 words added, 94 removed
1 unchanged line
PATIENT INFORMATION ZEPZELCA® (zep zel' kah) (lurbinectedin) for injection
What is ZEPZELCA? ZEPZELCA may be used to treat adults with a kind of lung cancer called small cell lung cancer (SCLC): •ZEPZELCA may be used in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs as maintenance treatment when your lung cancer: ois a type called “extensive-stage”, which means it has spread or grown, and ohas not progressed after first treatment with atezolizumab or atezolizumab and hyaluronidase-tqjs and the chemotherapy medicines carboplatin and etoposide. •ZEPZELCA may be used when your lung cancer: ohas spread to other parts of the body (metastatic), and oyou have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working. It is not known if ZEPZELCA is safe and effective in children.
Before receiving ZEPZELCA, tell your healthcare provider about all of your medical conditions, including if you: •have liver or kidney problems. •are pregnant or plan to become pregnant. ZEPZELCA can harm your unborn baby. Females who are able to become pregnant: oYour healthcare provider should do a pregnancy test before you start treatment with ZEPZELCA. oYou should use effective birth control (contraception) during treatment with and for 7 months after your last dose of ZEPZELCA. oTell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZEPZELCA. Males with female partners who are able to become pregnant should use effective birth control during treatment with and for 4 months after your last dose of ZEPZELCA. •are breastfeeding or plan to breastfeed. It is not known if ZEPZELCA passes into your breastmilk. Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your last dose of ZEPZELCA. Talk to your healthcare provider about the best way to feed your baby during treatment with ZEPZELCA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ZEPZELCA works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
1 unchanged line
What should I avoid while using ZEPZELCA? •Avoid eating or drinking grapefruit, Seville oranges, or products that contain grapefruit juice and Seville oranges during treatment with ZEPZELCA.
What are the possible side effects of ZEPZELCA? ZEPZELCA can cause serious side effects, including: • Low blood cell counts. Low blood counts including low neutrophil counts (neutropenia) and low platelet counts (thrombocytopenia) are common with ZEPZELCA, and can also be severe. Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death. Your healthcare provider should do blood tests before you receive each treatment with ZEPZELCA to check your blood cell counts. Tell your healthcare provider right away if you develop: ofever or any other signs of infection ounusual bruising or bleeding otiredness opale colored skin • Liver problems. Increased liver function tests are common with ZEPZELCA and can also be severe. Your healthcare provider should do blood tests to check your liver function before you start and during treatment with ZEPZELCA. Tell your healthcare provider right away if you develop symptoms of liver problems including: oloss of appetite onausea or vomiting opain on the right side of your stomach-area (abdomen) • Skin damage at or near the infusion site. ZEPZELCA can cause damage and death of tissue cells if it leaks into the tissues around your infusion site. You may need to have surgery to remove any dead tissue. Tell your healthcare provider right away if you see any fluid leaking at or around the catheter during your infusion, or if you notice any redness, swelling, itching or discomfort at the infusion site at any time. • Severe muscle problems (rhabdomyolysis). Treatment with ZEPZELCA may increase the level of an enzyme in your blood called creatine phosphokinase (CPK). Your healthcare provider should do blood tests to check your CPK levels before you start and during treatment with ZEPZELCA. Tell your healthcare provider if you have severe muscle pain or weakness. Your healthcare provider may temporarily stop treatment, lower your dose, or permanently stop ZEPZELCA if you develop serious side effects during treatment with ZEPZELCA. The most common side effects of ZEPZELCA given alonewith atezolizumab include: •tiredness •low white and red blood cell counts •increased kidney function blood test (creatinine) •increased liver function blood tests •increased blood sugar (glucose) •nausea •decreased appetite •muscle and jointtiredness (musculoskeletal)or painweakness •low levelincreased ofliver albuminenzymes in the blood •constipation •trouble breathing •low levels of sodium and magnesiumcalcium in the blood •vomiting •cough •diarrhea The most common side effects ofincreased ZEPZELCAkidney givenfunction withblood atezolizumabtest include:(creatinine) •low whitemuscle and red blood celljoint counts(musculoskeletal) •nauseapain •tirednessdecreased orappetite weakness•diarrhea These are not all of the possible side effects of ZEPZELCA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.
General information about the safe and effective use of ZEPZELCA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about ZEPZELCA that is written for health professionals.
What are the ingredients in ZEPZELCA? Active ingredient: lurbinectedin Inactive ingredients: sucrose, lactic acid and sodium hydroxide. Distributed by: Jazz Pharmaceuticals, Inc. Palo Alto, CA 94306 Under license from Pharma Mar, S.A. ZEPZELCA is a registered trademark of Pharma Mar, S.A. For more information, go to www.ZEPZELCA.com or call 1-800-520-5568.
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 0209/2026

Unchanged: Dosage forms and strengths, Contraindications, Drug interactions, Description, Clinical pharmacology, Nonclinical toxicology, References, How supplied, Patient counseling information, Package/label principal display panel, Package/Label Display Panel.

Every version

10 versions of set 632bb50c-3bcb-4c85-9056-fc33410550ae, newest first.
VersionPublished on DailyMedCompareSPL file
10Oct 2, 2026Shown belowDownload .zip
9Mar 16, 2026With version 8Download .zip
8Oct 6, 2025With version 7Download .zip
7Jul 3, 2025With version 6Download .zip
6May 15, 2025With version 5Download .zip
5Aug 11, 2023With version 4Download .zip
4Apr 15, 2022With version 3Download .zip
3Oct 4, 2021With version 2Download .zip
2Jun 23, 2021With version 1Download .zip
1Jun 17, 2020First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.